Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction

Montalescot, Gilles; W.J. van ’t Hof, Arnoud; Lapostolle, Frédéric; Silvain, Johanne; Flensted Lassen, Jens; Bolognese, Leonardo; J. Cantor, Warren; Cequier, Ángel; Chettibi, Mohamed; G. Goodman, Shaun; Hammett, Christopher; Huber, Kurt; Janzon, Magnus; Merkely, Béla; F. Storey, Robert; Zeymer, Uwe; Stibbe, Olivier; Ecollan, Patrick; M.J.M. Heutz, Wim; Swahn, Eva; Collet, Jean‐Philippe; F. Willems, Frank; Baradat, Caroline; Licour, Muriel; Tsatsaris, Anne; Vicaut, Éric; W. Hamm, Christian

doi:10.1056/nejmoa1407024

Public

Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction

Published in New England Journal of Medicine • Sep 1, 2014

Authors:

Gilles Montalescot

Arnoud W.J. van ’t Hof

Frédéric Lapostolle

Abstract

BACKGROUND: The direct-acting platelet P2Y12 receptor antagonist ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospital admission to patients with ST-segment elevation myocardial infarction (STEMI). Whether prehospital administration of ticagrelor ca...

Subject

Ticagrelor

Elevation (ballistics)

Myocardial infarction

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!